Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

15.8%

19 terminated/withdrawn out of 120 trials

Success Rate

79.1%

-7.4% vs industry average

Late-Stage Pipeline

25%

30 trials in Phase 3/4

Results Transparency

71%

51 of 72 completed trials have results

Key Signals

13 recruiting51 with results14 terminated5 withdrawn

Enrollment Performance

Analytics

Phase 2

25(27.5%)

Phase 3

25(27.5%)

Phase 1

19(20.9%)

N/A

16(17.6%)

Phase 4

5(5.5%)

Early Phase 1

1(1.1%)

91Total

Phase 2(25)

Phase 3(25)

Phase 1(19)

N/A(16)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (120)

Showing 20 of 120 trials

NCT05560646Phase 2Completed

A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Role: collaborator

NCT06559891Not ApplicableRecruiting

THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

Role: collaborator

NCT07000110Recruiting

Anifrolumab Malignancy and Serious Infections Study

Role: collaborator

NCT06712563Recruiting

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

Role: collaborator

NCT02734004Phase 1Active Not Recruiting

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

Role: collaborator

NCT04877691Phase 3Active Not Recruiting

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

Role: collaborator

NCT03881488Phase 1Completed

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Role: collaborator

NCT06042049Phase 3Completed

A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab

Role: collaborator

NCT06973161Completed

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

Role: collaborator

NCT04498117Phase 3Active Not Recruiting

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Role: collaborator

NCT03297281Not ApplicableRecruiting

Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)

Role: collaborator

NCT06799221Unknown

Expanded Access Program for OOS Obe-cel

Role: collaborator

NCT06203457Phase 2Completed

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome

Role: collaborator

NCT06504446Phase 2Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

Role: collaborator

NCT05243680Phase 3Completed

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Role: collaborator

NCT06073652Not ApplicableActive Not Recruiting

Starter Infant Formula With Synbiotics

Role: collaborator

NCT05101187Phase 3Active Not Recruiting

Olorofim Aspergillus Infection Study

Role: collaborator

NCT05874804Not ApplicableCompleted

Carry Life@ UF System Clinical Study

Role: collaborator

NCT04280029Not ApplicableActive Not Recruiting

SELUTION SLR™ 014 In-stent Restenosis